Giselle Sholler: New Neuroblastoma Trial Aims to Reduce Treatment Toxicity in Children
Giselle Sholler/ LinkedIn

Giselle Sholler: New Neuroblastoma Trial Aims to Reduce Treatment Toxicity in Children

Giselle Sholler, Division Chief of Pediatric Hematology/Oncology/BMT at Penn State Health, shared on LinkedIn:

“I am so proud to announce the opening of our new trial for children with neuroblastoma that I have been wanting to do for so many years!

As we have improved targeted therapies in neuroblastoma including DFMO as maintenance therapy, and incorporation of Naxitamab in induction therapy, our goal has always been to decrease the toxicity our patients undergo during transplant.

With these other treatments in place, we will evaluate the replacement of transplant with chemoimmunotherapy in children with high risk Neuroblastoma and evaluate both toxicities, and outcomes.

As Study Chair and Sponsor, I am so thankful to the opportunity to work closely with Jacqueline Kraveka, Bill Ferguson, Genevieve Bergendahl and the entire study committee from Beat Childhood Cancer Research Consortium at Penn State College of Medicine as well as our patient advocates from Beat Childhood Cancer Foundation and the team at SERB Pharmaceuticals to build the study design and bring this to fruition. So many caring people dedicated to evaluating ways to bring a better future for children with neuroblastoma so that our patients can survive and thrive!”

You can also read: